Moda Biotechnology
First-in-class drugs targeting immunometabolism for autoimmune diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Series A | |
| Total Funding | 000k | ||
Moda Biotechnology, also known as META Pharmaceuticals Inc., is a biopharmaceutical company established in August 2021, focusing on developing first-in-class drugs in the field of immunometabolism. The company leverages AI and biomedical research to discover and validate new therapeutic targets, aiming to create safer and more effective treatments for a variety of chronic conditions, including autoimmune diseases, cancer, and metabolic disorders.
The company was co-founded by Ke Xu and Anjin Xianyu. The founding team originates from prominent U.S. research institutions, Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center, and possesses deep expertise in immunometabolism, having researched the biological mechanisms that regulate immune cell metabolism for nearly eight years. Ke Xu serves as the CEO and previously worked as a consultant at PreScouter Inc., advising well-known biotech companies.
Moda Biotechnology's business model centers on the asset creation and out-licensing of its proprietary drug pipeline. The company's main products include small molecule inhibitors like Meta-01, Meta-02, and Meta-03, which target various autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and ulcerative colitis. One of its key candidates, META-001-PH, is a small molecule drug for treating primary hyperoxaluria, a rare pediatric disease, and has received Orphan Drug Designation from the U.S. FDA. Revenue is generated by providing these specialized drugs for autoimmune and metabolic diseases.
The company is jointly incubated by AI-pharmaceutical leader XtalPi, Forcefield Ventures, and IMO Ventures, with additional investments from firms like Tiantu Capital, Yael Capital, and Decent Capital. In February 2025, the company raised a Series A funding round to advance two pipeline drugs into clinical trials and expand its AI-driven target discovery platform.
Keywords: immunometabolism, autoimmune diseases, first-in-class drugs, small molecule inhibitors, biopharmaceutical, metabolic diseases, therapeutic targets, AI drug discovery, orphan drug, primary hyperoxaluria, META Pharmaceuticals, Ke Xu, Weill Cornell Medicine, Sloan Kettering, XtalPi, autoimmune disorders, drug development, clinical trials, venture capital